Effect of Subcutaneous Unfractionated Heparin Prophylaxis on Activated Partial Thromboplastin Time: A Retrospective Evaluation

被引:9
|
作者
Thompson, Molly H. [1 ]
Wilson, Sylvia H. [2 ]
Toussaint, Brittany L. [1 ]
Jordan, Cameron L. [1 ]
Hayes, Genevieve L. [1 ]
McKinzie, Brian P. [1 ]
Wolf, Bethany J. [3 ]
Field, Larry C. [2 ]
机构
[1] Med Univ South Carolina, Dept Pharm Serv, 150 Ashley Ave,MSC 584, Charleston, SC 29425 USA
[2] Med Univ South Carolina, Dept Anesthesia & Perioperat Med, 167 Ashley Ave,Suite 301,MSC 912, Charleston, SC 29425 USA
[3] Med Univ South Carolina, Dept Publ Hlth Sci, 135 Cannon St,Suite 303,MSC 835, Charleston, SC 29425 USA
关键词
Unfractionated heparin; Venous thromboembolism prophylaxis; Activated partial thromboplastin time; DEEP-VEIN THROMBOSIS; NEURAXIAL ANESTHESIA; PULMONARY-EMBOLISM; VENOUS THROMBOSIS; ANALGESIA; OBESITY; TRIALS;
D O I
10.1016/j.jclinane.2015.11.020
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Study Objective: Characterize the incidence of elevated aPTT results in patients treated with prophylactic, subcutaneous unfractionated heparin (UFH). Design: Retrospective, cohort analysis. Setting: Single-center, university hospital. Measurements: Evaluation of 257 patients with activated partial thromboplastin time (aPTT) testing both prior to and following subcutaneous (SC) unfractionated heparin (UFH) therapy. Main Results: Evaluated patients received UFH 5000 units every 8 hours. Baseline aPTT values were within the normal range (mean +/- SD, 32.0 +/- 8.5 seconds). After initiation of UFH, aPTT values increased (mean SD, 37.6 +/- 15.2 seconds). After 24 hours of SC UFH, mean aPTT values (mean SD, 38.6 +/- 15.5) exceeded the normal laboratory range (23.3-35.7 seconds). An elevated aPTT result after UFH was associated with baseline aPTT, length of therapy, and weight-based UFH dose. A significant association was not identified between aPTT elevation and age, race, sex, history of liver disease, type of admission, or transfusion of blood products. Conclusions: Treatment with UFH resulted in a small, but significant, increase in aPTT. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:346 / 350
页数:5
相关论文
共 50 条
  • [21] The use of activated partial thromboplastin time versus antifactor Xa assay in monitoring continuous unfractionated heparin infusion therapy in obstetric intensive care unit
    Hany V. Zaki
    Marwa A.K. Elbeialy
    Ahmed M. Soliman
    Ain-Shams Journal of Anesthesiology, 11
  • [22] The use of activated partial thromboplastin time versus antifactor Xa assay in monitoring continuous unfractionated heparin infusion therapy in obstetric intensive care unit
    Zaki, Hany, V
    Elbeialy, Marwa A. K.
    Soliman, Ahmed M.
    AIN SHAMS JOURNAL OF ANESTHESIOLOGY, 2019, 11 (1)
  • [23] Concordance Between Active Partial Thromboplastin Time and Anti-Factor Xa Assays in Neurocritically Ill Patients Receiving Subcutaneous Heparin Prophylaxis
    Shinn, Grace
    Berger, Karen
    Roh, David
    Doyle, Kevin
    Boehme, Amelia K.
    Connolly, Edward Sander
    Park, Soojin
    Agarwal, Sachin
    Claassen, Jan
    Der-Nigoghossian, Caroline
    NEUROHOSPITALIST, 2023, 13 (03) : 221 - 227
  • [24] Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time
    Koestenberger, M
    Cvirn, G
    Gallistl, S
    Muntean, W
    BLOOD COAGULATION & FIBRINOLYSIS, 2004, 15 (08) : 693 - 697
  • [25] Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: A systematic review and meta-analysis
    Swayngim, Rebecca
    Preslaski, Candice
    Burlew, Clay Cothren
    Beyer, Jacob
    THROMBOSIS RESEARCH, 2021, 208 : 18 - 25
  • [26] A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin
    Belk, K. W.
    Laposata, M.
    Craver, C.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (11) : 2148 - 2157
  • [27] LOW-DOSE HEPARIN IN ROUTINE HEMODIALYSIS MONITORED BY ACTIVATED PARTIAL THROMBOPLASTIN TIME
    SHAPIRO, WB
    FAUBERT, PF
    PORUSH, JG
    CHOU, SY
    ARTIFICIAL ORGANS, 1979, 3 (01) : 73 - 77
  • [28] Evaluation of the activated partial thromboplastin time and its influential factors in ischemic heart disease patients under heparin treatment
    Rezagholizadeh, Afra
    Adib, Zainab-Kubra
    Entezari-Maleki, Taher
    BLOOD COAGULATION & FIBRINOLYSIS, 2021, 32 (07) : 496 - 503
  • [29] Anti-Factor Xa and Activated Partial Thromboplastin Time Measurements for Heparin Monitoring in Mechanical Circulatory Support
    Adatya, Sirtaz
    Uriel, Nir
    Yarmohammadi, Hirad
    Holley, Christopher T.
    Feng, Amy
    Roy, Samit S.
    Reding, Mark T.
    John, Ranjit
    Eckman, Peter
    Zantek, Nicole D.
    JACC-HEART FAILURE, 2015, 3 (04) : 314 - 322
  • [30] Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time
    Kindelin, Nicole M.
    Anthes, Ananth M.
    Providence, Sarah M.
    Zhao, Xinhua
    Aspinall, Sherrie L.
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (05) : 575 - 583